KatznelsonLAtkinsonJLCookDMEzzatSZHamrahianAHMillerKK; American Association of ClinicalEndocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly–2011 update. Endocr Pract. 2011;17(suppl 4):1–44.
2.
GiustinaAChansonPBronsteinMD; Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95(7):3141–3148.
3.
ColaoAFeroneDMarzulloPLombardiG. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102–152.
4.
BergCPetersennSLahnerH; Investigative Group of the Heinz Nixdorf Recall Study and the German Pegvisomant Observational Study Board and Investigators. Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab. 2010;95(8):3648–3656.
5.
SherlockMAyukJTomlinsonJW. Mortality in patients with pituitary disease. Endocr Rev. 2010;31(3):301–342.
6.
OrmeSMMcNallyRJCartwrightRABelchetzPE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998;83(8):2730–2734.
7.
AyukJClaytonRNHolderGSheppardMCStewartPMBatesAS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab. 2004;89(4):1613–1617.
8.
Kauppinen-MakelinRSaneTReunanenA. Anationwide survey of mortality in acromegaly. J Clin Endocrinol Metab. 2005;90(7):4081–4086.
9.
CannavoSAlmotoBCavalliG. Acromegaly and coronarydisease: an integratedevaluation of conventionalcoronaryriskfactors and coronarycalcificationsdetected by computedtomography. J Clin Endocrinol Metab. 2006;91(7):3766–3772.
10.
BogazziFBattollaLSpinelliC. Riskfactors for development of coronaryheartdisease in patients with acromegaly: a five-yearprospectivestudy. J Clin Endocrinol Metab. 2007;92(11):4271–4277.
11.
TreppRStettlerCZwahlenMSeilerRDiemPChristER. Treatment outcomes and mortality of 94 patients with acromegaly. Acta Neurochir (Wien). 2005;147(3):243–251.
12.
AkutsuHKreutzerJWasmeierG. Acromegaly per se doesnotincrease the risk for coronaryarterydisease. Eur J Endocrinol. 2010;162(5):879–886.
13.
López-VelascoREscobar-MorrealeHFVegaB. Cardiacinvolvement in acromegaly: specificmyocardiopathy or consequence of systemichypertension?J Clin Endocrinol Metab. 1997;82(4):1047–1053.
14.
RajasooryaCHoldawayIMWrightsonPScottDJ, Ibbertson HK.Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 1994;41(1):95–102.
15.
PereiraAMvan ThielSWLindnerJR. Increased prevalence of regurgitantvalvular heart disease in acromegaly. J Clin Endocrinol Metab. 2004;89(1):71–75.
16.
DamjanovicSSNeskovicANPetakovMS. High output heart failure in patients with newly diagnosed acromegaly. Am J Med. 2002;112(8):610–616.
17.
MerolaBCittadiniAColaoA. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab. 1993;77(3):790–793.
18.
MinnitiGMoroniCJaffrain-ReaML. Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalicpatients. Clin Endocrinol (Oxf). 2001;55(3):307–313.
19.
RizzoMMikhailidisDP. There is more to predicting vascular disease than just established risk factors. Curr Pharm Des. 2011;17(33):3608–3610.
20.
KirilovGZacharievaSAlexandrovASLozanovVMitevV. Increased plasma endothelin level as an endothelial marker of cardiovascular risk in patients with active acromegaly: a comparison with plasma homocysteine. Methods Find Exp Clin Pharmacol. 2009;31(7):457–461.
21.
VilarLNavesLACostaSSAbdallaLFCoelhoCECasulariLA. Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly. Endocr Pract. 2007;13(4):363–372.
22.
EremCNuhogluIKocakM. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI. Endocrine. 2008;33(3):270–276.
23.
RizzoMPerniceVFrasheriA. Small, dense low-density lipoproteins are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome. Clin Endocrinol. 2009;70(6):870–875.
24.
RizzoMBerneisKCorradoENovoS. The significance of low-density lipoproteins size in vascular diseases. Int Angiol. 2006;25(1):4–9.
25.
MikhailidisDPElisafMS, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol. 2011;9(5):531–532.
26.
MikhailidisDPElisafMS, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9(5):533–571.
27.
RizzoMMikhailidisDP. Lipoprotein alterations and reduced growth hormone secretion: relationships with obesity and cardiovascular risk. Clin Endocrinol (Oxf). 2012;76:177–178.
28.
TanKCPangRWTiuSCLamKS. Effects of treatment with Sandostatin LAR on small dense LDL and remnant-like lipoproteins in patients with acromegaly. Clin Endocrinol (Oxf). 2003;59(5):558–564.
29.
ArosioMSartoreGRossiCMCasatiGFagliaGManzatoE. LDL physical properties, lipoprotein and Lp(a) levels in acromegalicpatients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group. Atherosclerosis. 2000;151(2):551–557.
30.
BoeroLCunibertiLMagnaniN. Increased oxidized low density lipoprotein associated with high ceruloplasmin activity in patients with active acromegaly. Clin Endocrinol (Oxf). 2010;72(5):654–660.
31.
RizzoMMikhailidisDP. Lipoprotein alterations and reduced growth hormone secretion: relationships with obesity and cardiovascular risk. Clin Endocrinol (Oxf). 2012;76:177–178.
32.
NordestgaardBGChapmanMJRayK; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–2853.
33.
ErqouSThompsonADi AngelantonioE. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol. 2010;55(19):2160–2167.
BoeroLManavelaMGómez RossoL. Alterations in biomarkers of cardiovasculardisease (CVD) in activeacromegaly. Clin Endocrinol (Oxf). 2009;70(1):88–95.
36.
KartalIOflazHPamukçuB. Investigation of earlyatheroscleroticchanges in acromegalicpatients. Int J Clin Pract. 2010;64(1):39–44.
37.
BrevettiGMarzulloPSilvestroA. Early vascular alterations in acromegaly. J Clin Endocrinol Metab. 2002;87(7):3174–3179.
38.
ColaoASpieziaSCerboneG. Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin Endocrinol (Oxf). 2001;54(4):515–524.
39.
PaisleyANBanerjeeMRezaiM. Changes in arterial stiffness but not carotid intimal thickness in acromegaly. J Clin Endocrinol Metab. 2011;96(5):1486–1492.
40.
BoysanSNKantarciF1CelikOMihmanliI1GaziogluN2KadiogluP. Atherosclerotic risk factors and premature atherosclerosis in acromegaly before and after 48 months of octreotide-LAR treatment. Angiology. 2012;63(7):522–527.
41.
JayasenaCNComninosANClarkeHDonaldsonMMeeranKDhilloWS. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Clin Endocrinol (Oxf). 2011;75(2):220–225.
